| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
BMS-351 manufacturers
- BMS-351
-
- $1980.00
-
2026-05-11
- CAS:1370001-71-0
- Purity:
- Supply Ability: 10g
|
| | BMS-351 Basic information |
| Product Name: | BMS-351 | | Synonyms: | BMS-351;1H-Benzimidazole, 4-(4-methyl-3-pyridinyl)-1-(2,2,2-trifluoroethyl)- | | CAS: | 1370001-71-0 | | MF: | C15H12F3N3 | | MW: | 291.27 | | EINECS: | | | Product Categories: | | | Mol File: | 1370001-71-0.mol |  |
| | BMS-351 Chemical Properties |
| Boiling point | 404.5±55.0 °C(Predicted) | | density | 1.31±0.1 g/cm3(Predicted) | | pka | 4.82±0.20(Predicted) |
| | BMS-351 Usage And Synthesis |
| Description | BMS-351 is a potent and selective, nonsteroidal CYP17A1 lyase inhibitor with robust selectivity over steroidogenic CYPs 21A2 and 11B1. BMS-351 emerges as an outstanding preclinical candidate to treat CRPC and is likely to minimize the side effects of current therapies due to its exceptional selectivity. BMS-351 is potentially useful for the Treatment of Prostate Cancer. | | Uses | BMS-351 (compound 18) is a potent, oral active, nonsteroidal CYP17A1 lyase inhibitor with the IC50 values of 19 nM and 4 nM aganist human CYP17A1 and cynomolgus monkeys CYP17A1,respectively. BMS-351 can be used for the study of castration-resistant prostate cancer[1]. | | References | [1] Huang A, et al. Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer. ACS Med Chem Lett. 2015;7(1):40-45. Published 2015 Dec 2. DOI:10.1021/acsmedchemlett.5b00310 |
| | BMS-351 Preparation Products And Raw materials |
|